Table 1.
Patient demographics and clinical characteristics.
| Characteristic
|
n
|
%
|
|---|---|---|
| Gender | ||
| Male | 22 | 37 |
| Female | 38 | 63 |
| Age (years) | ||
| Median | 61 | |
| Range | 30–82 | |
| Race | ||
| White | 52 | 88 |
| Black or African ancestry | 5 | 8 |
| Hispanic | 2 | 4 |
| Performance status | ||
| 0 | 19 | 32 |
| 1 | 37 | 62 |
| 2 | 4 | 7 |
| Diagnosis | ||
| Carcinoid | 30 | 50 |
| pNET | 30 | 50 |
| Elevated baseline chromogrinin A | ||
| No | 10 | 17 |
| Yes | 48 | 80 |
| Unknown | 2 | 3 |
| Baseline chromogrinin A | ||
| Median | 474 | |
| Range | 2–72 400 | |
| Primary site | ||
| Small bowel | 20 | 33 |
| Pancreas | 30 | 50 |
| Rectal | 1 | 2 |
| Lung | 6 | 10 |
| Gastric | 1 | 2 |
| Unknown | 2 | 3 |
| Grade | ||
| Low | 53 | 88 |
| Intermediate | 5 | 8 |
| Unspecified | 2 | 3 |
| Concurrent sandostatin | ||
| No | 26 | 43 |
| Yes | 34 | 57 |
| Prior lines of therapy | ||
| Median | 2 | |
| Range | 0–9 | |
| Octreoscan positivity | ||
| No | 9 | 15 |
| Yes | 36 | 40 |
| Unspecified | 15 | 25 |